ATE347904T1 - Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert - Google Patents

Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Info

Publication number
ATE347904T1
ATE347904T1 AT99956777T AT99956777T ATE347904T1 AT E347904 T1 ATE347904 T1 AT E347904T1 AT 99956777 T AT99956777 T AT 99956777T AT 99956777 T AT99956777 T AT 99956777T AT E347904 T1 ATE347904 T1 AT E347904T1
Authority
AT
Austria
Prior art keywords
associated antigens
cancer
universal tumor
antigens including
htert
Prior art date
Application number
AT99956777T
Other languages
English (en)
Inventor
Lee M Nadler
William C Hahn
Joachim L Schultze
Robert H Vonderheide
Original Assignee
Dana Farber Cancer Inst Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22309530&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347904(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Whitehead Biomedical Inst filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE347904T1 publication Critical patent/ATE347904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99956777T 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert ATE347904T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10610698P 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
ATE347904T1 true ATE347904T1 (de) 2007-01-15

Family

ID=22309530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956777T ATE347904T1 (de) 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Country Status (7)

Country Link
US (1) US7851591B1 (de)
EP (1) EP1126872B1 (de)
AT (1) ATE347904T1 (de)
AU (1) AU1331100A (de)
CA (1) CA2344972A1 (de)
DE (1) DE69934426T2 (de)
WO (1) WO2000025813A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
EP1171612A2 (de) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-spezifisches krebsimpfstoff
CA2390882A1 (en) * 1999-11-15 2001-05-25 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using cytochrome p450 1b1
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003070752A2 (en) * 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CN1306027C (zh) * 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
JP5070045B2 (ja) 2004-05-27 2012-11-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規人工抗原提示細胞およびそれらの用途
WO2006009838A2 (en) 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
EP2337795A2 (de) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc-multimere in krebsimpfstoffen und der untersuchung der immunreaktion
JP6042211B2 (ja) 2010-02-16 2016-12-14 ウルティモバックス エーエス ポリペプチド
EP2388014A1 (de) * 2010-05-21 2011-11-23 Dorkoosh, Farid Abedin Therapeutische Anwendung von tumoralen Peptiden mit variabler Immunoglobulinregion bei Patienten mit B-Zell-Malignomen
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
MA40253A (fr) 2014-07-15 2017-05-24 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CN110573173A (zh) 2016-09-30 2019-12-13 宾夕法尼亚大学理事会 Tert免疫原性组合物及使用其的治疗方法
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US5747317A (en) 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
CA2266752A1 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase

Also Published As

Publication number Publication date
AU1331100A (en) 2000-05-22
EP1126872A1 (de) 2001-08-29
US7851591B1 (en) 2010-12-14
CA2344972A1 (en) 2000-05-11
EP1126872B1 (de) 2006-12-13
DE69934426T2 (de) 2007-10-04
DE69934426D1 (de) 2007-01-25
WO2000025813A1 (en) 2000-05-11
EP1126872A4 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
ATE347904T1 (de) Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU7697301A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
SI1187632T1 (sl) Zdravljenje z anti-ErbB2 protitelesi
HK1046287A1 (en) Ibd-associated microbial antigens and methods of using same
IL195338A0 (en) Optimized fc variants and methods for their generation
DE69727966D1 (de) Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
MXPA05014016A (es) Proteinas portadoras para vacunas.
YU84903A (sh) Antitela koja blokiraju cripto i njihova upotreba
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
NO992916D0 (no) Fosfodiesterase 8A
ATE331791T1 (de) Phosphodiesterase 10
WO1999067384A3 (en) Prostate cancer-associated genes
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO2000060080A3 (en) Molecules of the immune system
UY26170A1 (es) Antigeno (c42) asociados a tumores
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO1999031225A3 (en) Human phosphatases
WO2003024304A3 (en) Detection and treatment of cancers of the liver
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties